Innovative Food Holdings (IVFH) Update: The Activist Investor Thesis

IVFH is a SPECULATIVE opportunity. The nano cap led by a shareholder aligned management team and board with substantial skin in the game.

Innovative Food Holdings enters Q1 2026 as a different company. After disappointing Q4 2025 results, the board forced the CEO's resignation and completed the Pennsylvania warehouse sale. As a result, IVFH has changed leadership and is an asset-light operation. The balance sheet is now clean following the sale of its Pennsylvania facility and the closure of its cheese business. These changes have created a focused and simplified company.

Management said the online demand isn't broken. Integration, ERP, onboarding, and platform transitions are current weaknesses. Although management believes sales will recover after modernization. However, the turnaround works only if management stabilizes revenue growth and improves margins.

IVFH is a long shot! But if the company maintains or increases margins and is consistently profitable. Innovative Food Holdings becomes a more valuable company.

Risks

A few customers make up most of the revenue. US Foods accounts for 37% of revenue, Gate Gourmet 14%, and Sam's Club 12%. Two-thirds of total sales come from these three customers. Single customer accounts for 23% of receivables. And, management revealed that it relies on a major distributor.

The turnaround is still a question. Although the remaining high-margin platform has the potential to grow revenue organically. Liquidity has improved, but cash is only $1.23M. IVFH is now financially clean but not debt-free. The company still carries liabilities, including leases, separation costs, and acquisition debt.

Liquidity is tight, with only ~1 million in cash. Also, management is working to address fragmented systems, manual processes, integration, forecasting, procurement, and service. Management believes fixing these problems may take longer than expected. Loss of a major customer will materially impact their results. 

The company made material changes in a short period. This includes management shifts, acquisitions, business closures, and major asset sales. While these actions improve the business over time. They also increase execution risk. 

Financial reporting and IT controls had material weaknesses. This is not a major threat. But it raises concerns about the reliability of financial reporting, which management must address.

Food distribution is a highly competitive business. And the IVFH operates with gross margins of about 26%, which leaves limited room for error. Operations have low margins, and rising freight and transportation costs. Even small operational mistakes impact profitability.

The company's CFO (Gary Schubert) was promoted to CEO in December 2025 after the CEO's removal. And the search for a replacement CFO is still ongoing. These management changes may be positive.

As a result, the risk of major financial distress is lower than in the past. However, risks remain. Cash generation is still limited. Future acquisitions will require additional financing. The company's cash flow can be volatile, with large potential losses due to its high customer concentration.

Opportunities:

IVFH has developed relationships with hundreds of specialty food producers over the past 27 years. Niche food companies are too small and specialized to sell to these large distributors. So, IVFH distributes these vendors' products using its technology platform, including onboarding, integration, and listing. IVFH lists these specialty items with the large foodservice distributors. Distributors add them to their ordering systems so that chefs and restaurants can place orders.

A chef/restaurant places an order through one of the largest distributors. The order is routed in real time via IVFH's platform to the vendor. IVFH handles vendor agreements, rebates, and administrative tasks. Small producers can't handle it. The product is drop shipped directly to the customer, bypassing the distribution center. IVFH's growth doesn't come from building inventory facilities or buying trucks. It comes from adding more vendors and items. No more inventory risk with higher margins than traditional storage fulfillment. Fast, fresh delivery of unique items that large distributors don't stock themselves. Network effects include more vendors, distributors, and chef orders as more vendors join.

IVFH's dropship digital channel connects artisan producers with major distributors and chefs with no inventory required. This makes IVFH's business highly scalable. It has very low capital and operating expense requirements in comparison to traditional distribution.

Management discussed the time to onboard new specialty food vendors. This used to take 6–12 months, limiting growth. Although they have added AI, staff, and improved processes. If successful, this will significantly speed up onboarding and enhance revenue growth.

Execution and expansion of existing opportunities were the messages of the Q1 2026 conference call. Also, compared to Q4 2025, ERP updates, process improvements, AI, and cash preservation were discussed.

Total liabilities fell from $13.3M to $4.0M quarter-on-quarter. Operating income rose to $350K, up from last year's $260K, despite a 19% revenue decline. The company is now simple and profitable with an improved balance sheet.

The company's value increases substantially if revenue and margins remain consistent in its niche food distribution business. However, if revenue continues to decline, fair value will likely move closer to the tangible book value of .13.

Q1 2026 Sales were down 19%. But they still made a greater profit than in the prior-year period, with margins improving to 26%. Systems must be modernized, and revenue must be maintained. Earnings power could be substantially higher than current results suggest. The stock price should be significantly higher than the current price of .29.

The revenue decline was due to the company's exit from the retail cheese business. Although Q1 2026 operating income increased. This despite a 19% decline in revenue. IVFH is sacrificing lower-quality revenue while improving the economics of the remaining business. US Foods' sales must stabilize to support a higher stock price. Revenue can improve through better customer onboarding and a narrower focus.

IVFH is heavily influenced by activist investors and economically aligned with shareholders. The board and small-value hedge funds have an outsized influence over the company, owning most of the outstanding shares. Their average share price paid is nearly + twice the current price. They are not selling.

The upside is substantial at the current price for speculative investors willing to gamble on a turnaround. IVFH has completed the company's financial restructuring.

Ownership, Incentives, and Board Alignment

Innovation Food has an advantage with its ownership.

Officers and directors own approximately 46.9% of IVFH. That is unusually high. It creates strong alignment among management, the board, and external shareholders. Microcap executives often prosper regardless of stock performance. But IVFH’s leadership team is directly tied to IVFH's price.

Chairman James Pappas owns 19.1% of the company. Pappas is not a food industry executive. Instead, he has an investment banking background in mergers and acquisitions, as well as corporate governance. Papas did activism at Jamba, The Pantry, U.S. Geothermal, and Morgan's Foods. They were sold. He worked in leveraged finance, recapitalizations, and corporate transactions at Goldman Sachs and Bank of America.

His background is relevant. Because many of IVFH's actions over the last two years resemble an activist playbook. The success of these steps remains to be seen. However, they suggest a board focused on improving intrinsic value rather than preserving the status quo.

Director Denver Smith is a hedge fund manager and CFA. His investment group owns 9% of the company. And his investment background adds to capital allocation decisions and fiscal oversight.

The board is further strengthened by Mark Schmulen. An entrepreneur and investor with experience in venture-backed technology businesses, digital marketing, and private investing. While IVFH is not a technology company, Schmulen brings an important perspective. This is valuable as the company proceeds to develop its ecommerce and customer acquisition capabilities.

CEO Gary Schubert worked at Walmart for 15 years and at Tyson Foods for 3 years. His background includes business transformation, merchandising, finance, and ecommerce strategy.

IVFH's board combines activist investors, experienced capital allocators, entrepreneurs, and operators. The combination is overlooked. Although the company still confronts significant business risks. The people responsible have financial incentives and the professional experience to execute.

Management’s Compensation

Executive compensation supports shareholders. CEO Gary Schubert's long-term compensation is heavily tied to stock performance.

Executive equity awards vest if IVFH's stock price increases severalfold. Schubert's has stock price targets ranging from $2.45 to $4.08. Approximately 3.5 million shares of awards are tied to executive incentive plans.

Management's large equity rewards are not guaranteed. Executives cannot realize the value of these awards if shareholders don’t benefit from considerable stock appreciation. At current prices, major performance awards remain far out of the money.

This creates a favorable incentive structure. Management is rewarded not simply for remaining employed, but for increasing the value of the business and the stock. Management and directors have strong financial incentives to create long-term stockholder value.

IVFH has extremely concentrated ownership. Insiders own 46.9% of the company. The major shareholders include James Pappas (19.1%), Bandera (11.3%), the Denver Smith group (9.0%), Intelligent Fanatics (6.6%), and Harper (5.2%). A small group of investors effectively controls the company and has major influence over key decisions.

Valuation:

I think the current $0.29 price reflects the worst-case scenario. The market capitalization is $15 million, and the enterprise value is $14.5 million.

If valuation multiples revert closer to earlier levels. The stock could be worth substantially more. The current EV/Revenue multiple is 0.30x. A return to 0.50x implies a value of about $0.63 per share. The current EV/EBITDA multiple is 6.59x. A return to 15x implies about $0.61 per share. The current EV/EBIT multiple is 9.23x. A return to 20x would mean about $0.58 per share. Together, these methods suggest a base-case value range of $0.60 per share.

These represent base-case valuations in the $0.58- $ 0.63-per-share range. If the company resumes growth, adds more vendors, and improves profitability, a share price of more than $1.00 is achievable.

IVFH is profitable, with an improved balance sheet, customer lists, and trade names/domains.

Conclusion

IVFH is a speculative turnaround. The stock trades at depressed prices after major operational and management changes. The company exited low-quality revenue. And sold non-core assets, strengthened its balance sheet, improved margins, and was profitable despite a large revenue decline. Now management must focus on consistent sales, modernize systems, improve onboarding, and reduce its dependence on a few large customers.

The bull case ultimately comes down to execution. If revenue stabilizes and management successfully scales its high-margin, asset-light platform, the current valuation is below the company's earnings potential. The company's ownership, activist-influenced board, and executive incentives are positive for shareholders.

Investors must realize the substantial risks. Customer concentration is high, liquidity is tight, and turnaround is unproven. Failure to stabilize revenue could push the stock closer to tangible book value. Successful execution will push the share price higher. For speculative investors, IVFH offers an asymmetric opportunity.

Long IVFH

PetMeds (PETS): The Hidden Cost Cutting Opportunities That Could Drive a Return to Profitability

PetMed's market price has been hit hard by declining revenue. Revenue fell from $227 million in FY2025 to $179 million in FY2026. The stock trades as if survival is in question.

Now the question is how PetMeds can become profitable again. During the recent earnings call, management announced that they saved about $6.1 million a year. That is not enough. Material additional savings exist if management aggressively right-sizes the business.

Management has already taken steps to improve efficiency and reduce costs. The company has reorganized its pharmacy, call center, and distribution operations. Headcount was reduced, and existing underperforming vendor relationships ended. Furthermore, they implemented a new ERP system, a new call center platform, and a fraud-prevention system. Together, it's expected to generate approximately $6.1 million in annualized cost savings.

Let’s examine the remaining opportunities for meaningful cost savings.

Consolidate to One Distribution Center

This may be the largest hidden opportunity. PetMeds currently operates two pharmacy and distribution facilities. One in Delray Beach, Florida, and Lynbrook, New York, versus annual revenues of $179 million. It might not be economical to have two warehouses, pharmacies, and duplicate inventory. Consolidating operations will lower facility expenses, utilities, rent, and property costs. Savings would also include warehouse payroll and inventory carrying costs. Estimated annual savings could be $2 million to $4 million. The main risk is that the New York pharmacy license may have strategic value. This consolidation could negatively impact delivery times for Northeast customers. The estimated savings are not supported by any direct evidence from management.

Call Center Automation

PetMeds mentions investments in AI, automation, call center technology, and digital customer service. Customer service remains a significant operating expense. Routine order inquiries, such as prescription refills, shipping, and autoship, can be automated. A 10% to 20% reduction in customer service staffing could generate annual savings of 1 to 2 million. The savings are primarily due to reduced headcount is reasonable but not proven.

Corporate Overhead

PetMeds currently employs approximately 189 people while generating $179 million in annual revenue. The company has also experienced significant executive turnover. Currently operating with an interim CEO and interim CFO. PetMeds still has opportunities to streamline its corporate structure. Human resources, finance, legal, compliance, and marketing could all gain efficiency. Estimated annual savings are $1 million to $3 million. The saving thesis is reasonable, but not directly supported by company disclosures.

Marketing Efficiency

Management has stated that it is shifting marketing spending. Advertising expenses totaled approximately $5.8 million in the fourth quarter. And roughly $23 million annually. Even a modest 10% reduction in advertising costs could save more than $2 million a year.

Eliminate Low Margin Categories

Management disclosed a failed wholesale initiative. The $2.1 million inventory write-off indicates expanding into low margin items. Potential candidates include low-margin foods, bulky products, and slow-moving inventory. A focused SKU program could reduce inventory levels and lower working capital requirements. EBIT improvement is possible in the estimated range of $0.5 million to $2 million. This is hard to prove quantitatively because the evidence for the savings is indirect.

Procurement and Supplier Rebates

According to the 10-K, 88% of PetMeds' inventory purchases come from ten suppliers. This level of supplier concentration provides meaningful negotiating leverage. Potential opportunities include securing better supplier rebates, improved payment terms, and volume discounts. Even modest improvements in procurement costs could have a significant impact on profitability. The estimated annual savings are $1 million to $3 million; the estimate is speculative.

Public Company Costs

PetMeds is a NASDAQ-listed company with a market capitalization of  $35 million. Expenses include audits, SEC compliance, legal fees, board compensation, and investor relations. Management has also highlighted elevated professional fees during the past year. If PetMeds were acquired by an outside party. Many of these costs could be eliminated immediately. Estimated annual savings are $2 million to $4 million. It's for the reasons a strategic buyer might pay a premium.

The opportunity for additional cost savings appears significant. Distribution consolidation could generate $2 million to $4 million annually. Call center automation may contribute another $1 million to $2 million. Streamlining corporate overhead could save $1 million to $3 million. And marketing optimization may provide an additional $1 million to $2 million. SKU rationalization could improve EBIT by $0.5-$2 million. Supplier negotiations may add another $1 million to $3 million. In total, these initiatives could yield an annual profit improvement of approximately $6.5 million to $16 million.

Can PETS Reach a Positive EBITDA?

Based on FY2026 results, PetMeds reported revenue of $179 million and a net loss of $57.3 million. Adjusted EBITDA in the fourth quarter was approximately negative $2.8 million. Annualizing suggests the business is currently operating at roughly negative $10 million to negative $12 million of EBITDA.

So, additional cost reductions of $6 million to $10 million could potentially move the company into a positive EBITDA of $2 million to $8 million.

If revenue stays around current levels and management executes the announced and additional cost-saving measures. PetMeds could generate positive EBITDA of $5 million to $12 million without returning to the $227 million revenue level it reached a year ago.

Conclusion

The $6.1 million savings number has hard evidence from management. THE OTHER SAVINGS ESTIMATES ARE ASSUMPTIONS, NOT COMPANY GUIDANCE!

Long PETS

The PetMeds (PETS) Board: Uniquely Qualified to Create Value Through a Turnaround or Acquisition

Analysis of the PetMeds Board

The PetMeds board of directors has proven expertise in strategy, operations, and capital allocation. This combination will support future shareholder value.

Peter Batushansky brings successful and proven industry experience. He founded and built Allivet. Allivet was one of PetMed's largest competitors before Batushansky sold the business to Tractor Supply (TSCO) in 12/2024. He understands customer acquisition, prescription fulfillment, veterinary relationships, margins, and industry consolidation. Also, he knows what buyers look for in a pet pharmacy business. If PetMeds gets more acquisition offers. His experience will be invaluable.

James LaCamp is the audit chair and joined the board in October 2025. LaCamp, at 42, is still an active operating executive. He is currently the CFO at Skydio. Previously, he was CFO of Flock Safety, SVP of Finance at Coupa Software, and an audit partner at Deloitte. He has an accounting degree from Santa Clara University, an MBA from Wharton, and is a CPA. 

LaCamp was not recruited for his expertise in the pet industry. Instead, he brings deep experience in financial analysis, capital allocation, M&A, corporate strategy, and value creation. He will be another key director in evaluating a turnaround, a restructuring, a strategic review, or a company sale.

Justin Mennen has expertise in technology and digital retail. Since PetMeds competes against much larger online players such as Chewy and Amazon. His background is relevant. His skill set will be used as PETS improves its technology, customer retention, marketing efficiency, online conversion rates, and turnaround.

Leah Solivan is the founder of TaskRabbit. She brings together experience in entrepreneurship and a company sale. She built and sold a successful company to IKEA. She understands both value creation and value realization. Her background suggests an objective approach. If a turnaround offers the best return? She would likely support.

Leslie Campbell joined the board in 2018 and became the Chair in January 2024. She accepted the role as Interim CEO in August 2025. This was after the departures of both the CEO and CFO. Further, Campbell held senior roles at Oracle and Dell. Her expertise is in finance, technology, governance, and board oversight.

Campbell is not an activist investor or turnaround specialist. But several factors make her more open to strategic alternatives than prior management. She purchased 60,000 shares in the open market in late 2024. Her career has focused on governance and shareholder oversight rather than empire building. This could make her more open to a transaction.

The recent leadership change as an Interim CEO may create an opportunity for the board to reassess strategy. The company still possesses valuable assets, a recognized brand, pharmacy licenses, and a large customer base with recurring autoship revenue. These attributes could make it attractive to strategic buyers.

Although the board recently declined two acquisition offers in 12/2025, Campbell's priorities as Interim CEO are likely to be stabilizing operations and recruiting permanent executive leadership. The most probable outcome is that the board will first attempt to improve performance while continuing to review all strategic alternatives, as publicly stated in the most recent quarterly results.

Conclusion

The board is uniquely strong for a company of PetMeds' size. Batushansky provides proven direct competitor expertise, backed by hands on operations and company sales. LaCamp contributes financial and strategic discipline. Mennen adds technology and digital commerce experience. And Solivan brings entrepreneurship and M&A knowledge. This is combined with Interm CEO Campbell's background in governance. The board appears built to evaluate a wide range of options.

Additional information on valuation. 

As mentioned earlier, board member Peter Batushansky founded, built, and sold Allivet. He sold it to TSCO in 12/2024 for 135M. Because Allivet was privately owned. Its financial results were not publicly disclosed. But we can attempt to make estimates based on what is known about the transaction.

Tractor Supply (TSCO) bought Allivet for $135 million in cash. Further, TSCO said in a press release following its announcement of the purchase of Allivet. Allivet could generate $1 billion in revenue at full scale. However, it's based on future potential. Allivet served pet owners online as a licensed online pet pharmacy for over 30 years. The exact same businesses as PETS, with headquarters in Florida.

Using the $135M Allivet's sale price. What was Allivet's estimated annual revenue? Pet pharmacies and e-commerce businesses are often bought for 0.5x to 1.5x revenue, or 8x to 15x EBITDA. A valuation of 0.75x revenue means annual sales of $180 million, and 1.0x revenue means $135 million.

Based on these valuation ranges, Allivet's estimated annual revenue is between $100 million and $200 million. Allivet’s annual revenue for 2024 is likely to be less than PETS’ $189M trailing 12 months of revenue. This is an estimate based on acquisition multiples, not a public figure.

The key takeaway is that Allivet appears profitable enough for Tractor Supply to pay $135 million for it. In contrast, PetMed is currently losing money and burning cash. That profitability difference likely explains the valuation gap between the two companies.

PetMeds investors should focus on whether the company can return to profitability. If PetMeds could eliminate its losses and generate $10–15 million annually. PETS could support a valuation closer to Tractor Supply's Allivet. PETS has a market cap of 35M, and owns 35M in Florida real estate with 185M in TTM sales. In theory, if PETS becomes profitable, its market value should be several times higher. However, if losses continue and cash burn persists, the comparison to Allivet isn't meaningful.

Long PETS

PetMed Express (PETS): High-Risk Turnaround, Hidden Assets, Activism

PetMed Express (PETS) is a declining pet pharmacy and pet healthcare company. The current market valuation fails to account for several factors. Such as cash, real estate, prior acquisition interest, and signs of turnaround efforts. Two prior acquisition bids were $4-4.25 per share. Yes, revenue and margins were declining. And the share price has fallen. Further, concerns have increased due to competition. The current valuation suggests investors are forecasting a significant deterioration in the franchise. Execution risk is substantial. Although the existing assets provide material downside support. Continued operating losses will quickly reduce the margin of safety.

The current valuation suggests investors are pricing in a significant deterioration in the franchise value. Any meaningful improvement will create material upside in the stock price. Ultimately, the investment case depends less on asset values. But on whether management can stabilize revenue and translate operational improvements into earnings.

PETS lacks a permanent CEO. Or an interim CEO with experience in the pet pharmacy industry. Leadership stability is critical to turnarounds. An interim CEO makes for additional activist or new acquisition talks. Interim leadership might emphasize immediate value realization over long-term transformation.

Risks:

According to the latest 10Q, revenue fell 22.7%, and reorder sales declined 22.6%. Operating cash flow was –$23.7M. The $26.7M in goodwill was fully impaired due to lower forecasts and a declining market value. The $2.1M inventory write-down indicates operational errors. With interim leadership, it's hard to turn a company around.

PETS is a high-risk turnaround. The business is shrinking. Although the balance sheet provides time. The stock trades at around $2.20, with a market cap of $46M and an enterprise value of $19.22M. Latest data show cash fell from the prior-year balance of $ 54.72M to $26.9M due to negative operating cash flow.

Additional risks include permanent customer losses to competitors such as Chewy and Amazon. And failure to successfully integrate PetCareRx, continued cash burn, lack of permanent leadership, margin pressure from pricing competition and discounting, and possible further impairment of brand value

Opportunities:

PETS is mostly an asset backed special situation.

Management initiatives include cost reductions, PetCareRx integration, autoship expansion, digital improvements, and veterinary offerings.

The market price ignores the values of owned assets. PETS has $26.9M in cash, $12.2M in inventory, $1.6M in accounts receivable, $27.6M in property and equipment, and $32.8M in shareholder equity. Liabilities consist of normal operating costs rather than debt obligations. Investors are overlooking asset values that exceed GAAP.

The company owns its 14.60-acre Delray Beach, Florida headquarters and distribution facility, along with 2 acres of excess land. Based on comparable South Florida industrial and commercial property values. The Delray property may be worth approximately $35M. Although the exact market value is uncertain. This creates potential upside with a sale-leaseback or renewed outside interest.

For the nine months ended December 31, 2025, PETS generated $136.2 million in sales. Reorder sales were $112.7 million, representing approximately 83% of total sales. New order sales were $18.6 million, while membership fees contributed $4.9 million. The revenue continues to come from existing and repeat customers.

Additional assets include the PetMeds brand and PetCareRx trade name. And internet domains, toll-free customer assets, and a $5.3M investment in Vetster. Additionally, management reduced costs and inventory by integrating PetCareRx. Digital operations are improving, and Telehealth is expanding. Inventory dropped from $16.2M to $12.2M. When an asset-heavy company trades below its estimated private value. Strategic outcomes, such as the sale of the company, increase.

Activist/acquisition

SilverCape announced in December 2025 that it would take PETS private for $4.00 a share. And changed its 13G status to 13D, making it the largest outside investor. They increased their ownership stake to 12.20% (2,579,696 shares). Management stepped up and used a poison pill to prevent SilverCape from acquiring more than 13% of the outstanding shares.  Soon after, Cardone Ventures submitted a cash offer of 4.25. Cardone mentioned the value of the PETS brand. Including its customer relationships, pharmacy platform, and operating infrastructure. Other major value investors have also acquired positions. Nina Capital owns about 8.8% and has added to its position through open-market purchases. Pinnacle Value Fund acquired a position in 2025 at an average price of $2.84 per share. As of February 2026, Diveroli Investment Group owned 391,757 shares, equal to roughly 1.83% of PETS.

There is also reason to believe that acquisition discussion may still be possible. SilverCape's proposal said it would "engage constructively" with the Board and management. Furthermore, neither management nor SilverCape publicly stated that negotiations or discussions had ended. Because SilverCape still owns over 12% of the company, strategic discussions cannot be ruled out. Although there is no public evidence that negotiations continue. We shouldn't discount the possibility of PETS going private.

Sum of the parts valuation

Valuation Ratios

With any hint of turnaround success, the valuation will increase substantially.

Additional reasons for a higher valuation:

Reorder sales are 83% of total sales. PETS still owns customer relationships and brands. There is no debt burden, although its operating liabilities are large. And the Delray property may be worth over 40M.

The margin of safety is supported by cash, real estate, customer assets, and a minority investment in Vetster. Significant upside still may depend on management stabilizing operations and converting repeat customers into sustainable profits.

Conclusion:

PETS is more of an asset-backed special situation than an operational turnaround. As I said, PETS has declining revenue, competitive pressure, large cash burn, and leadership uncertainty. The assets are not reflected in the current market price.

Prior acquisition offers of $4.00–$4.25 per share suggest that value exists beyond earnings power. Liquidation value has less impact on the investment. But instead, focus more on whether management can stabilize operations. And convert its large base of repeat customers into profitability. If the turnaround gains traction or strategic alternatives emerge, the upside could be substantially higher prices. But if operating losses continue, the safety margin shrinks. For investors comfortable with high risk, I believe PETS may offer asymmetric risk/reward for speculative investors.

Long PETS

Precision Optics (POCI): A High Risk, Potential High Reward Microcap Transition Story

Precision Optics is transforming from a niche engineering supplier to a large manufacturer. If management executes effectively. This transition could drive outsized earnings growth and a higher stock price.

Precision Optics makes specialized devices and lighting components used in the medical market. It also provides custom optical components for industrial, defense, and aerospace applications. Precision Optics offers design, prototyping, regulatory support, and manufacturing. Founded in 1982 and based in Massachusetts, with operations in Maine and Texas. Precision Optics (POCI) uplisted to the Nasdaq in 2022. At the time, management said their goal was to improve visibility, increase institutional sponsorship, and improve liquidity.

The recent $10M public stock offer at $3.60 was oversubscribed. Investors included existing shareholders and new value institutional investors. Further, the CEO, CFO, COO, and directors bought shares in the recent offering at the same terms as outside investors.

Now the question for investors. Can POCI transform from a thinly traded microcap into a small med tech growth company?

The transformation is becoming more visible when looking at the prior 3 quarters. Q1 2026 revenue was 6.70M, Q2 2026 was 7.4 M, and the most recent reported Q3 2026 was 8.70M. Gross margins also had a major recovery, from 14.40% in Q1, 2.80% in Q2, and 24% in the most recent Q3 2026. Adjusted EBITDA went from negative to positive in Q3 2026.

Risks:

Execution remains the largest risk and is discussed during conference calls. Management highlighted low yields, scrap costs, labor inefficiencies, and training challenges. Gross margins fell to 2.8% in Q2, and EBITDA guidance shifted from a projected profit to a meaningful loss. This suggests management underestimated the difficulty of scaling.

Customer concentration remains significant. A large portion of revenue depends on a small number of customers. During Q3, an aerospace customer requested a temporary production slowdown. This shows how results can change if a key customer delays or reduces orders. While recent financing has improved liquidity, dilution risk has not disappeared. And capital may be needed if profitability takes longer than expected. POCI is a small manufacturer. It is struggling to prove it can convert revenue growth into sustainable earnings

Opportunities:

Precision Optics is transitioning from a small engineering company to a production manufacturer. Potentially creating attractive operating leverage.

Management stated that we are operating at a record level on the latest Q3 2026 conference call. This was evident as revenue increased from $6.7 million in Q1, $7.4 million in Q2, and to a record $8.7 million in Q3 2026.

POCI's aerospace business may be a valuable hidden asset. Its satellite-related programs generate roughly $3.6 million in quarterly revenue. And production yields are improving to 97%. This implies an annual revenue run rate of $14-15 million for a single customer. In addition to aerospace, the company supports attractive medical markets. Such as cystoscopes, ophthalmic devices, arthroscopy, urology, and otoscopy. Management says these segments are growing at mid to high-teen annual rates. Furthermore, medical products create sticky customer relationships. Because of their long product life cycles and regulatory barriers. Also, the recent $10 million financing reduces near term financial risk.

Valuation Metrics: 

Comparison to Peers

POCI = 52 Week price change = 6.43%,current ratio = 2.10, book value 2.10, revenue per share = 3.10,quarterly revenue growth (yoy) =  108.00%

Management's technical background and shareholder alignment provide a foundation as the company moves from a niche engineering business into a larger manufacturing operation. From 2006 to 2011, the CEO was the company's Executive Vice President and Chief Scientific Officer. He earned a PhD in Applied Physics from Princeton University, and he holds an MA in Mechanical/Aerospace Engineering. He's an optical and imaging guy, so his background makes sense.

Cataylst:

Management must move beyond simply using its proprietary micro optics and imaging technologies to provide services and develop new products. And successfully transition to profitable large scale manufacturing. When higher production volumes convert into consistent earnings and cash flow. The market will value it more as a growing medical technology manufacturer. Continued institutional interest will increase visibility and reduce the discount on microcap stocks.

I started with a long position in POCI. POCI is a high risk idea. But I would recommend POCI as a speculative investment.

Long POCI

Debt Free Operational Reset, Innovative Food Holdings IVFH

 
Innovative Food Holdings (IVFH) is a nanocap specialty food distributor undergoing a more focused asset-light model. Shares trade at $0.82 with 54.8 million shares outstanding and a market value of $44.9 million. Public float is 28.7 million shares or 23.5 million.

By selling their Pennsylvania warehouse and closing the unprofitable cheese business in 2025, management proved they can make difficult pro-shareholder decisions. Eliminating the Pennsylvania warehouse will yield quarterly savings of approximately $200,000 in interest, while closing the unprofitable cheese business will enhance gross margins.Further, management is growing the Digital Channels business, which adds more products and vendors without inventory. Their use of AI helps accelerates onboarding,jumping from 13 items historically to 400 items added in just four weeks. Meanwhile, the airline catering segment grew 26% year-on-year.

A debt-free balance sheet, margin recovery, a scalable platform, and multiple expansions create a higher stock price.

Business Overview:
Innovative Food Holdings (IVFH) distributes specialty foods through an asset-light digital network (Sysco, US Foods, Amazon) and a fast-growing airline catering arm (+26% YoY, Q2 2025). Recent acquisitions (Golden Organics, LoCo) have expanded regional capacity and fed into its digital catalog. Meanwhile, the airline business is consolidated in Chicago for efficiency.

Recent Developments (Q2 2025)
IVFH posted $21.1M revenue (+27% YoY) with airline catering up 26% and Amazon triple-digit growth; the remaining improved sequentially. Reported gross margin was 21% but ex-cheese margin expanded by 66 bps. OCF turned positive (+$575K vs. -$977K in Q1), net income swung to $59K, and the cheese exit plus the pending PA warehouse sale (Sept. 2025) set up lean, higher-margin operations.

Catalyst:
The following two quarters, ~$9M of debt is retired by Q4 2025, reducing ~$200K/quarter in interest expense and leaving IVFH nearly debt-free. The exit from the unprofitable cheese business removes a structural drag, while the Chicago consolidation unlocks SG&A leverage and pushes margins toward the mid-20s. At the same time, AI-driven catalog expansion accelerates growth, with onboarding speed cut by ~80% and thousands of high-margin SKUs ready to launch. Airline catering continues to compound (+26% YoY) with embedded recurring revenue and ongoing customer wins adding upside. With valuation at just 0.66× EV/Sales-well below peers at 1-2×-and normalized EBITDA power set to re-rate sharply, the timing offers investors a rare window before cleaner results and balance sheet optics force the market to close the gap.

Ownership
Activist shareholders with skin in the game on the board is a game changer.Innovative Food Holdings has unusually aligned ownership for a turnaround.

Pappas owns 18% of the company's shares and has been on the board since 2020. His background in restaurants and distribution makes IVFH an easy fit for his playbook. He's a proponent of "growth activism" - fixing capital structures, installing operators, and aligning governance with customers.
 

Bandera Partners holds ~12% and Denver Johnson Smith ~9%. Inlight Wealth (~5%) and Intelligent Fanatics (~5.5%) add to the institutional sponsorship. Collectively, these funds control >45% of equity. Insider alignment is meaningful: CEO Bill Bennett owns ~4.5%, COO Brady Smallwood holds option grants based on performance, and director Hank Cohn retains ~5%. The result is a concentrated, shareholder-friendly register where activists and management align economically. Active ownership is critical. The company misallocated and devalued assets for years. It anchors capital discipline, enforces board refreshment, and supports operating playbooks built for growth. Large value-oriented shareholders directly impact strategy and capital allocation. Value-based activist ownership will guide improved capital allocations, forcing a clear path to create long-term value.

Valuation:
At just 0.66× EV/Sales, IVFH trades at a steep discount to distribution peers Sysco (1.0×), US Foods (0.9×), and Performance Food Group (0.8×). A re-rating to 1.0× implies ~50% upside. At $0.82/share, IVFH offers material upside with multiple opportunities to accelerate growth and margin expansion.

Risks:
Margin and growth risks include accelerated catalog growth and recent acquisition integrations. Customer concentration remains a factor, with U.S. Foods still representing a large distribution channel and subject to competitive pressure. As a thinly traded small-cap, IVFH shares carry liquidity, risk and volatility. Finally, the expected synergies from the Denver acquisition have not yet been proven, leaving room for integration challenges if management falls short.

Conclusion:
IVFH is an overlooked micro-cap entering a turnaround phase. Multiple catalysts, including debt elimination, AI-driven catalog expansion, airline catering growth, and margin recovery, are set to re-rate the valuation. At just 0.66× EV/Sales, the stock trades well below its peers despite intrinsic value estimates pointing to 2-3× upside. A small, ignored company undergoing a balance sheet and operating reset, where execution through Q4 2025 and after creates potential for asymmetric returns.

Long:IVFH 

Tandy Leather TLF: Dear Chairman

 Today's post updates the risks and opportunities associated with the recent real estate sale and also contains a message for the Chairman of the board.

Business Summary:

• Tandy Leather (TLF), founded in 1919, is the profitable leader of the leather crafting retail market. 

• TLF sells leather and leather craft-related items primarily through retail stores, websites, or direct account representatives. 

• Tandy has 101 stores in 40 states, six provinces in Canada, and one store in Spain. 
• Several smaller, privately family owned competitors exist, including Double Eagle Leathersmith, Montana Leather Company, and Weaver Leather Supply.

Tandy Leather announced on Dec 6th that its corporate headquarters was sold for $26.5 million before taxes/expenses. The expected closing date is sometime in January 2025. As part of its transition to new facilities in Fort Worth, Texas, Tandy will lease back the facilities until September 2025.

The announcement had a minimal impact on TLF's stock price. Before the announcement, the stock traded at approximately $4.20 per share over the trailing three months. Following the sale announcement, the price rose modestly to $4.75 per share. Given the stock’s limited trading volume, even this increase lacked significant momentum.

This muted market reaction is surprising, especially considering that the company’s liquidation value, by my conservative estimate, increased by 42%. This estimate assumes $15 million in additional net cash proceeds from the sale, based on a pre-announcement value of $35 million. My calculation factors in estimated real estate taxes and expenses of $11.5 million, leaving $15 million in net cash proceeds.

 

Dear Mr. Chairman,

I have been a dedicated shareholder of Tandy for many years, but I am increasingly concerned about the board’s operational oversight and strategic decision-making. My concerns stem from significant missteps, including the mishandling of inventory errors and the substantial expenditure on consultants, which squandered shareholder value.

The current CEO is 63 years old, and two CFOs have been hired and departed within two years. This instability raises serious questions about the board’s ability to identify and retain competent leadership for key positions. Why should shareholders trust the board to effectively replace a future CEO or CFO? Furthermore, how does the board intend to responsibly allocate proceeds from the headquarters sale, valued at $26.5 million?

Accountability for Inventory Errors
I believe the removal of former CFO Ms. Castillo following the discovery of inventory errors in Q4 2019 was a mistake. Despite this, the board has not taken accountability for the multi-year inventory errors or the lack of compliant systems that led to them. As a fiduciary body, the board is responsible for overseeing inventory management, ensuring system compliance, and approving budgets for improvements. Yet, the company relied on outdated, non-integrated systems—some stores even maintained paper records. These shortcomings culminated in regulatory penalties and significant value destruction, further eroding shareholder trust.

Financial Oversight Gaps
Since 2020, Tandy has recruited and lost two CFOs. These hires were ill-suited for the role, as evidenced by their short tenures. This reflects a glaring gap on the board—a lack of members with real-world corporate finance and operational experience. This deficiency has directly contributed to ongoing accounting irregularities. Why was Ms. Castillo removed in the first place, and how can shareholders trust the board to effectively select a new CFO given its track record?

Compensation Discrepancies and Shareholder Concerns
In FY 2023, Tandy, a $35 million nano-cap company, paid its CEO and a board member $1,181,280 in total compensation. The CEO now holds 439,285 shares, or 5.22% of shares outstanding, alongside generous annual stock options—such as 92,000 shares in 2022 with an exercise price of $3.52. These figures appear disproportionate to Tandy’s size and performance, particularly in light of the challenges faced since the discovery of inventory errors.

Cash Balance Decline and Cost Mismanagement
When inventory errors were identified in Q4 2019, Tandy’s audited cash balance stood at $25 million. By September 2022, when Tandy was relisted on NASDAQ, this had plummeted to $3 million. While inventory valuation issues did not impact cash directly, the precipitous decline reflects significant mismanagement. Currently, the cash balance sits at $10 million. What specific actions contributed to this erosion of cash reserves?

From 2019 to 2020, the company spent $5.5 million on restatement efforts and CFO transitions. Over two years, an additional $4.9 million was allocated to restatements, with $594,000 earmarked for CFO-related expenses, as disclosed in the 10-K. Despite these investments, the board failed to ensure the implementation of effective ERP and accounting systems, leading to ongoing inefficiencies and delays.

Relisting and Additional Costs
Tandy was delisted from NASDAQ in August 2020 after the board failed to prepare timely financial statements. It took nearly two years—and significant costs for financial consultants, ERP system advisors, and CFO transitions—for the company to regain its listing in July 2022. Between 2019 and 2022, millions of dollars were spent without clear disclosure of consultant costs, further frustrating shareholders.

The board must address these systemic failures and communicate a transparent plan for the future. As a shareholder, I urge you to take immediate action to restore confidence by improving oversight, ensuring accountability, and demonstrating a commitment to responsible financial stewardship.

 

Shareholders are not unreasonable in believing the upcoming cash infusion will evaporate. Furthermore, the proposed small dividend would do little to offer meaningful liquidity to long-term shareholders who have patiently supported the company for years.

 

Opportunities

The board must recognize that Tandy Leather Factory (TLF) is not suited to remain a publicly listed company. However, due to inertia, the company continues to bear unnecessary administrative and operational expenses, which serve no real benefit to shareholders or employees. A strategic sale of Tandy would unlock significant value and position the company for long-term health and growth under more suitable ownership.

Tandy's future lies with an entity capable of nurturing its potential for the benefit of all stakeholders. Based on NAV or EBITDA multiple valuations, Tandy could command a premium of over 65% above its current market value.

A new owner could realize over $1 million in annual savings by eliminating public company costs, including listing fees, audits, and legal expenses. These savings alone would contribute to immediate profitability improvements.

Since 2018, Tandy's EBITDA margins have averaged approximately 6.75%, generating an annual EBITDA of $5.4 million. However, for the 17 years prior, EBITDA margins averaged a much stronger 12.6%. If a new owner can drive modest revenue growth—boosting the current $76 million average revenue to $80 million—and restore historical EBITDA margins to 12%, Tandy’s annual EBITDA could reach $10 million.

This approach not only enhances operational efficiency but also provides a sustainable foundation for growth, benefiting employees, customers, and investors alike. The path forward is clear: a strategic sale would unlock Tandy's true value and secure its future.

 

Valuation using the Balance Sheet

These metrics all point to a much higher valuation over the current 38M.

Conclusion: NOW is the time to explore strategic alternatives.

 

I respectfully urge the Board of Directors to engage in a thorough review of strategic alternatives, including the potential sale of the company, to maximize shareholder value and ensure the long-term interests of all stakeholders are prioritized

The board must urgently develop and present a transparent plan to ensure shareholders have the opportunity to exit at a fair and reasonable price – no less than $7 per share. If the board cannot achieve this without pursuing a sale of the company, then it is imperative they explore and initiate a formal sale process without delay.

As Benjamin Graham wisely noted in Security Analysis:

"It is not the function of the corporation to make the market for its shares, but it should provide a fair and reasonable opportunity for stockholders who desire to dispose of their holdings to obtain an adequate price for them."

Currently, minority shareholders are being neglected and undervalued by Tandy’s board. This has persisted for far too long. Mr. Chairman, it is time to demonstrate goodwill and take meaningful action to address shareholder concerns.

 

Long TLF

 

HireQuest HQI: Asset-Light Franchising, Strategic Acquisitions, And Profitable Growth

 

HireQuest (HQI)

Price = $14.48: Market Cap = 200.16M : Enterprise Value = 215.19M

P/B = 3.04: EV/Revenue = 5.80 : EV/EBITDA = 19.26

HireQuest (HQI) is a fast-growing national staffing franchisor with a proven, profitable asset-light model. It has impressive historical operating margins and strong free cash flow. The CEO’s net worth is invested in +22% of HQI’s outstanding shares. His total HQI investment is 44 million, and he often makes open market purchases.

The staffing industry is highly fragmented.  And HQI has aggressively made strategic acquisitions, buying smaller competitors and integrating them into its franchise model. Refranchising acquired companies boosts profits by lowering the capital requirements, costs, and operating risk.

Top-line growth is evident. Revenue per share increased by 126.22% from the 2021 balance of 1.15 to the trailing twelve-month balance of 2.61. Profitability has materially grown. Per share, retained earnings, and book value grew by 283.09% and 87.54%, respectively, from 2021 to the current trailing 12 months. These value-increasing attributes have significantly outperformed its stock price performance, offering a mean reversion opportunity in addition to expanding multiples and value from additional growth. HQI’s price per share declined -23.01 % from the year ending 2021 to the current price of $14.25, contrasted to the material per share value improvement in retained earnings, book value, revenues, and a forward dividend yield of 1.68%. HQI declared a .06 dividend for shareholders of record 12/2/24. 

See the table below for historical financial performance.

Relative valuation using the NAISC code 561311 (employment placement agencies) for 14 companies.

HQI has the highest EBITDA margins, 30.11%, versus the NAISC (561311) average of -12.37%. The second-highest EBITDA margin was KFY at 12%. Sixteen insider buying transactions over the prior 12 months for HQI versus a medium of zero or three companies with one or two small insider purchases. Institutional ownership is 12.10% for HQI versus the average 60% for NAISC(561311). HireQuest's CEO purchased 18,459 shares in the open market in 2024 for $230,603 at an average price of 12.49. HQI directors purchased 7,000 shares for $89,080 at an average price of 12.73 in 2024. Since 2019, HQI insiders bought 346,889 shares for $3,216,348 at an average price of $9.27, with zero insider selling. Operationally, HireQuest consistently outperforms its peers!

A brief review of the most recent earnings for Q3 2024.

Revenue growth for Q3 2024 slowed to 1.60% year over year to $9.4 million, and sequential revenue growth was 8.5% compared to the second quarter of 2024. Temporary staffing brands grew by 3.6%, their first year-over-year growth since early 2023. Due to significant reductions in workers' compensation expenses, down 67% from last year, SG&A expenses dropped by +15% from Q3 2023.

Executive recruiting and permanent placement are long-term opportunities, but demand has been low. Due to a market downturn, MRI Network assets acquired in 2022 were impaired by $6 million. With the impairment charge removed, adjusted net income increased to $2.8 million. Adjusted EBITDA rose to $4.9 million with a 52% margin.

The company completed two small acquisitions in Q3. Management is actively looking for more deals, mainly in commercial staffing.

HireQuest expects better performance in 2025 due to market stabilization and cost control. Staffing market stability and disciplined expense management keep management optimistic.

Risk:

Economic downturns can reduce staffing demand.

Integrating acquisitions, such as MRI, introduces short-term margin compression and operational challenges.

Opportunities:

Through franchising, HQI can enter diversified staffing verticals and grow.

They can boost margins by buying and converting to their proven asset-light business model.  

The expanded national network enhances HQI’s ability to secure large contracts.

Franchises make HQI resilient to economic downturns. Companies may prefer temporary staffing solutions to full-time hires.

Conclusion:

HQI investment is a long-term buy. HireQuest stands out in the staffing industry because it has a proven asset-light franchise model, an aggressive acquisition strategy, management talent, and material ownership in the common stock. The company has grown in key financial metrics and adapted to economic changes. Despite recent price underperformance, the company's impressive prior four-year profitable operations, solid balance sheet, cost controls, and disciplined approach to acquisitions present a compelling mean reversion and growth opportunity.

Long HQI

Transforming agriculture with innovative seed technology: S&W Seed Company

S&W Seed (SANW) is a global agricultural business focusing on alfalfa, sorghum, pasture, and sunflower seeds. It develops proprietary products using plant breeding and molecular techniques and sells over 600 seed products. Cleaning and processing facilities are located in Texas, New South Wales, and South Australia. S&W seed products are sold in over 40 countries, and management expects to introduce 20 new products during 2024.

In June 2023, SANW hired Mark Herrmann as their CEO. With a remarkable 35 years of experience in the seed industry, including a significant tenure at Monsanto, Mark brings a wealth of knowledge and a fresh perspective to our team. His recent role as the CEO/Founder of ACUMEN and AgReliant Genetics further underscores his leadership capabilities and his potential to steer S&W Seed toward greater success.

CFO Vanessa Baughman joined SANW on 05/2023. She brings extensive seed industry experience and insight into seed industry finances. Her financial tenure was as CFO at AgReliant Genetics, the largest North American seed company, from January 2000 to January 2019, and as a finance executive at Monsanto Company.

 Initiatives and Financial Progress during Q3 2024 

Double Team's proprietary sorghum trait technology will be planted on over 10% of all acres in the United States during 2024, double the amount planted last year. This is a 77% to 115% increase compared to fiscal 2023. Over the next few years, a gradual adoption increase will occur, with a 25 percent market share goal by 2027. Double Team is one of the fastest growing seed traits on the market because of S&W's sorghum technology. Farmers are realizing the benefits of improved yield enhancement through grass control and crop grazing safety technologies. YTD margins were 29.2% compared to 23.2% last year. The advantages are evident with Double Team gross margins of ~ 60%. Further, SANW expects them to increase due to efficiency and stacking technologies. S&W is the key technology provider in sorghum.

Several initiatives were implemented to improve efficiency, increase inventory utilization, reduce product SKUs, and cut outsourcing costs. Further, a plan was introduced to reduce seed manufacturing costs and rationalize certain low-margin forage product lines.

International operations face several headwinds, especially in the Middle East, Northern Africa, and the MENA region. They've gotten worse since February.

The Double Team technology platform by S&W Seed  (SANW) improves profitability and productivity for sorghum grain farmers. Sorghum requires less water and energy than other crops like corn. The technology also helps farmers optimize their use of resources, leading to better profitability.

S&W Seed Company adopted a brand and licensing strategy to expand. They have signed licensing agreements with 15 independent seed companies, some of which offer Double Team under private labels.

Mexico, Brazil, Argentina, and Australia are some of S&W Seed Company's key international markets. The company plans to work with market leaders in these regions through license agreements, allowing it to carry and promote Double Team while paying royalties.

Within three years, the Double Team quickly gained market acceptance, capturing 10% of the U.S. sorghum market. This rapid adoption rate shows how valuable and practical the technology is for sorghum farmers. SANW is also working on DT2, which allows earlier weed spraying during the sorghum growth cycle. They also work on DT and Prussic Acid-Free (PAF) traits for weed control and livestock safety.

For fiscal 2024, adjusted EBITDA expectations are negative $6 million to $8 million. Despite the negative EBITDA expectation, the payments from Shell and Trigall are expected to cover operating cash needs for 2024. SANW received a $6 million payment from Shell in February 2024 and will receive a $1.4 million payment from Trigall. Beyond fiscal 2024, if growth continues in its sorghum portfolio and it achieves expense management initiatives, it will soon be near positive cash flow.

The table below provides additional quantitative value analysis.

Tangible BV is .53 per share versus the market's current price of .32.  P/TB = .60, EV/BV = 1.25, trading at historical lows. My enterprise value is calculated as market value + total liabilities less cash. EV/GP is 3.97, down from 13.73 for 06/2022. EV/Sales = .94, down from the 2021 value of 2.11. Debt per share is significant at 1.19 and slightly improved from 1.24 for 2023.

Properties owned: Warehouse ( Moore County, Texas); Processing facility/Warehouse (Lubbock County, Texas); Research farm (Keith, South Australia)

Opportunities: 

The new CEO and CFO have deep operational experience managing seed businesses and introducing new traits.

Management expects Double Team to be on over 10% of U.S. sorghum acres. Plus, licensing and partnerships for international growth.

A successful launch and growth of Double Team, DT Forage Sorghum, and Prussic Acid Free.

Investing in R&D to develop new traits and focus on non-GMO solutions. From 12/2019 to the MRQ, 30.23 million or .81 per share was spent on research and development for new products.

Material improvement and quickly expanding margins with Double Team sorghum. Management is focused on high-margin products. Quarter 3 2024 saw a 25% margin improvement over Q3 2023, with GM% of 23.56% versus 18.77%.

Partnership with Shell to develop Camelina for biofuels and explore strategic partnerships to diversify revenue.

Removing noncore programs and selling nonessential assets.

Risk

Geopolitical events, such as contract losses in the MENA region and supply constraints in Australia, negatively affected revenue and EBITDA guidance. 

Agriculture market conditions are unpredictable, and SANW lacks the liquidity to wait another two years. Working capital must be managed efficiently to cover operational needs and reduce liquidity risks. Material negative surprises will likely result in dilution or bankruptcy to pay debtors.

Conclusion:

S&W Seed has demonstrated impressive growth with Double Team and its future product pipeline. Strategic partnerships and focusing on high-margin products with low-cost partnerships and associated royalties offer value for investors willing to take on the risk.

Despite this, we cannot predict droughts, floods, geopolitical issues, or market acceptance of their current or future products. This, coupled with current debt, makes SANW a HIGH RISK investment.

However, given the current valuation and current and potential value of existing seed technology, I consider SANW a POSITIVE EXPECTED VALUE INVESTMENT. So, I'm buying SANW.

Long SANW (S&W Seed Company)

Consumer Cyclicals: Kambi Group (KMBIF) is statistically cheap

Kambi provides sports betting technology worldwide. Over 40 operators on six continents are part of their partnership. From compliance to odds-compiling, Kambi offers a wide range of services through its in-house software platform. Over 1,000 employees work at eight global locations: Malta (headquarters), Australia, Copenhagen, the Philippines, Romania, Sweden, the UK, and the US. 

My analysis is only quantitative and needs more work. I'm not making a recommendation but instead for additional research if interested.

Over the past few years, Kambi has lost its three largest customers. Kindred, Penn Entertainment, and DraftKings have purchased or developed internal solutions. However, the current price may offer an opportunity. The market may have overestimated the risk of Kambi's customers sourcing their sportsbook technology.

.

Enterprise value per share is 8.89. That's a decline of 71.12% from 30.77 at the end of 2020. Retained earnings per share rose 200.20% over the same period, from the MRQ balance of 4.66 versus the 2020 balance of 1.46. Ratios also improved, EV/Rev = 1.40 (85.46% improvement from 2020), EV/GP = 1.42 (66.60% improvement from 2020), and EV/Retained earnings = 1.91 (76.51% improvement from the 2020 balance of 21.11).

Kambi offers barriers to entry and switching costs. With its current low valuations, it could be an acquisition candidate. 

Risks: Loss of customers when companies develop or buy existing companies with solutions. Changes in technology and government regulatory changes.

Click to see a small part of the discovery process. 

No Position: Kambi Group (KMBIF)

Simple Screen: Discounted Real Estate, Share Buybacks, Debt Reduction, Transformation, Oversold

 JACK: Jack In The Box

Jack in the Box was founded in 1951 and operates and franchises fast food restaurants, Jack in the Box and Del Taco, throughout the U.S. The company is based in San Diego, California.

Jack in the Box is transforming from an asset-heavy and barely growing to a faster-growing, asset-light franchisor that is shareholder-friendly by monetizing real estate assets, dividends and improving its capital structure with share repurchases.

In addition to 189 restaurant-owned land locations, JACK owns its corporate headquarters in San Diego, California. The headquarters is 70,000 square feet and contains approximately four acres of undeveloped land. Its fair market value is around 40 million. Rent is earned at the land locations owned by JACK and used by the franchisee. 

IMO, at these prices, Jack in the Box stock is a weak intermediate-term buy and a stronger long-term buy. There's a high debt load, no obvious valuation discount to peers, and rising inflation for food and labor. Demand for fast food is weak, and the market is highly competitive.

Management is committed to maximizing shareholder value. Using the CF statement, over the past five quarters, debt payment was 91.73M, 45.60M was distributed as dividends, and 60.43M was spent on share repurchases.

Long JACK on 07/11/24

Click here to discover new ideas on 10,805 stocks listed in the USA exchanges for multiple countries. Use the filter on the right; if you want, export it to Excel for additional analysis.